Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04235621 · ClinicalTrials.gov registry record
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
A clinical trial, sponsored by Goldfinch Bio.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04235621 is a clinical trial that was terminated before completion, run by Goldfinch Bio. The registered enrollment target is 20 participants.
The verdict
NCT04235621 was terminated before completion, sponsored by Goldfinch Bio.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.
Interventions
- OTHER FSGS/TR-MCD
- OTHER Diabetic Nephropathy (DN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-05-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04235621
The ClinicalTrials.gov registry entry for NCT04235621 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldfinch Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FSGS/TR-MCD is the first listed.
NCT04235621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04235621 about?
NCT04235621 is a clinical study titled "A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)". This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine wi...
What is the current status of trial NCT04235621?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2019-12-20. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT04235621?
The interventions under investigation include: FSGS/TR-MCD (OTHER), Diabetic Nephropathy (DN) (OTHER).
Who is sponsoring clinical trial NCT04235621?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.